A prediction model of CKD progression among individuals with type 2 diabetes in the United States
- PMID: 36774851
- DOI: 10.1016/j.jdiacomp.2023.108413
A prediction model of CKD progression among individuals with type 2 diabetes in the United States
Abstract
Background: CKD progression among individuals with T2D is associated with poor health outcomes and high healthcare costs, which have not been fully studied. This study aimed to predict CKD progression among individuals with diabetes.
Method: Using ACCORD trial data, a time-varying Cox model was developed to predict the risk of CKD progression among patients with CKD and T2D. CKD progression was defined as a 50 % decline, or 25 mL/min/1.73 m2 decline in eGFR from baseline, doubling of the serum creatinine, or onset of ESKD. A list of candidate variables included demographic characteristics, physical exam results, laboratory results, medical history, drug use, and healthcare utilization. A stepwise algorithm was used for variable selection. Model performance was evaluated by Brier score and C-statistics. Confidence intervals (CI) were calculated using a bootstrap method. Decomposition analysis was conducted to assess the predictor contribution. Generalizability was assessed on patient-level data of the Harmony Outcome trial and CRIC study.
Results: A total of 6982 diabetes patients with CKD were used for model development, with a median follow-up of 4 years and 3346 events. The predictors for CKD progression included female sex, age at T2D diagnosis, smoking status, SBP, DBP, HR, HbA1c, alanine aminotransferase (ALT), eGFR, UACR, retinopathy event, hospitalization. The model demonstrated good discrimination (C-statistics 0.745 [95 % CI 0.723-0.763]) and calibration (Brier Score 0.0923 [95 % CI 0.0873-0.0965]) performance in the ACCORD data. The most contributing predictors for CKD progression were eGFR, HbA1c, and SBP. The model demonstrated acceptable discrimination and calibration performance in the two external data.
Conclusion: For high-risk patients with both diabetes and CKD, the tool as a dynamic risk prediction of CKD progression may help develop novel strategies to lower the risk of CKD progression.
Keywords: CKD progression; Diabetes; Prediction.
Copyright © 2023. Published by Elsevier Inc.
Conflict of interest statement
Conflict of interest There is no conflict of interest to report for all co-authors.
Similar articles
-
A prediction model on incident ESKD among individuals with T2D and CKD.J Diabetes Complications. 2023 Apr;37(4):108450. doi: 10.1016/j.jdiacomp.2023.108450. Epub 2023 Mar 1. J Diabetes Complications. 2023. PMID: 36871314
-
A prediction model on incident chronic kidney disease among individuals with type 2 diabetes in the United States.Diabetes Obes Metab. 2023 Oct;25(10):2862-2868. doi: 10.1111/dom.15177. Epub 2023 Jun 19. Diabetes Obes Metab. 2023. PMID: 37334525
-
Predicting incident heart failure among patients with type 2 diabetes mellitus: The DM-CURE risk score.Diabetes Obes Metab. 2022 Nov;24(11):2203-2211. doi: 10.1111/dom.14806. Epub 2022 Aug 8. Diabetes Obes Metab. 2022. PMID: 35801340 Free PMC article.
-
Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.Am J Kidney Dis. 2018 Nov;72(5):653-661. doi: 10.1053/j.ajkd.2018.02.364. Epub 2018 May 18. Am J Kidney Dis. 2018. PMID: 29784612
-
A Novel Kidney Failure Prediction Model in Individuals With CKD: Impact of Serum Bilirubin Levels.J Clin Endocrinol Metab. 2025 Apr 22;110(5):1375-1383. doi: 10.1210/clinem/dgae430. J Clin Endocrinol Metab. 2025. PMID: 38912790 Free PMC article.
Cited by
-
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population.Clin Kidney J. 2024 Mar 6;17(4):sfae052. doi: 10.1093/ckj/sfae052. eCollection 2024 Apr. Clin Kidney J. 2024. PMID: 38650758 Free PMC article.
-
Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease.J Manag Care Spec Pharm. 2025 Jul;31(7):641-650. doi: 10.18553/jmcp.2025.31.7.641. J Manag Care Spec Pharm. 2025. PMID: 40577033 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous